Ann: PAA completes Phase 1 and files for Orphan Drug Designation, page-54

First 54 Last

Share
Profile

Follow
Jakjazz

2,784 Posts.

1016

05/12/23

01:47

Post #: 71268831
Share

Originally posted by Jakjazz: ↑

Hi Kpax and NZTYour valuation estimate and commentary got my attention and for what its worth here is my 2 bobs worth.

Lets take your initial figures but apply a captured 60% market share as suggested by PTP which I believe is far more reasonable. Let’s also recognize that the incumbents stand to lose approx. $1.5 billion in revenue each year assuming they continue to sit on their hands and watch PAA take their market share. This is highly unlikely IMHO.

So if its $900 million gross revenue for 30% then its US$1.8 billion gross revenue for 60%. Now assuming MPL extends the life of the majority of MND patients this would be a conservative figure as the MND population on MPL would continue to grow (existing and new patients).

Based on a November 2023 report noting the gross margin of the top 15 BP ranged from 57% to 83% (https://www.statista.com/statistics/473429/top-global-pharmaceutical-companies-gross-margin-values/) let’s take a gross margin of 50% for PAA. Assuming a GP of 50% (rare disease with ODD) then that would give PAA a gross profit of $900 million per year.

Now “For pharmaceutical companies, the median gross profit margin was 76.5% (95% CI, 70.3%-82.7%), the median EBITDA margin was 29.4% (95% CI, 26.3%-32.5%), and the median net income margin was 13.8% (95% CI, 10.2%-17.4%)….3 Mar 2020.

Let's use 10% for a net profit and doing so PAA would generate an annual net profit of $90 million per year. If we then did an NPV (disc @ 10%) over 5 years with a terminal value of 3 years we would generate a value of $500 million for MND alone. This does not include any price escalation or increase in MPL treated population numbers.

Given the 2015 PAA valuation put a value on human and canine cancer at approx. $50 million then we could add that to the $500 million and add further value for covid and other potential diseases MPL may “cure”.

If this was done than a valuation in the order of $600 million to $1 billion is not without reason at this point in time.

Expand

E&OE

PAA Price at posting: 9.4¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

There are more pages in this discussion • 377 more messages in this thread...

First 54 Last

Add PAA (ASX) to my watchlist

(20min delay)
Last 21.0¢		Change 0.025(13.5%)		Mkt cap ! $85.12M

Open	High	Low	Value	Volume
20.5¢	22.0¢	20.0¢	$664.7K	3.211M

Buyers (Bids)

No.	Vol.	Price($)
3	115330	21.0¢

Sellers (Offers)

Price($)	Vol.	No.
21.5¢	28804	4

View Market Depth

No.	Vol.	Price($)
3	115330	0.210
7	154800	0.205
7	383328	0.200
3	79230	0.195
5	104533	0.190

Price($)	Vol.	No.
0.215	28804	4
0.220	164616	5
0.225	26060	2
0.230	73104	3
0.235	107209	3

Last trade - 15.08pm 31/05/2024 (20 minute delay)


Last 21.0¢		Change 0.025 ( 13.5 %)
Open	High	Low	Volume
20.5¢	22.0¢	20.0¢	1339603
Last updated 15.28pm 31/05/2024 ?

PAA (ASX) Chart

Ann: PAA completes Phase 1 and files for Orphan Drug Designation, page-54

Featured News

Talga shows expansion options for Sweden's Vittangi graphite project

Making the best of an inflationary environment

Telix testing shows efficacy of anti-prostate cancer therapy

Daily ASX Market Update: Health pushes shares into gain terrain - May 31, 2024

Thor reports 200% increase in tungsten at NT's Molyhil

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: PAA completes Phase 1 and files for Orphan Drug Designation, page-54

Featured News

Top Stories

Talga shows expansion options for Sweden's Vittangi graphite project

Making the best of an inflationary environment

Telix testing shows efficacy of anti-prostate cancer therapy

Daily ASX Market Update: Health pushes shares into gain terrain - May 31, 2024

Thor reports 200% increase in tungsten at NT's Molyhil

Buyers (Bids)

Sellers (Offers)

Featured News